GH

Guardant Health, Inc. (GH) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2025. Guardant Health is a precision oncology company providing blood and tissue tests for cancer screening, monitoring, and treatment selection. Key products include the Guardant360 suite for advanced cancer, Guardant Reveal for early-stage recurrence monitoring, and the Shield blood test for colorectal cancer screening, which received FDA approval and Medicare coverage in late 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 21% year-over-year, driven by a 20% increase in Oncology revenue (volume growth to ~59,000 tests) and the introduction of Screening revenue ($5.7 million) from the Shield test.
• Expense Increases: Sales and marketing expenses rose 30% to $104.3 million due to commercial team expansion and Shield launch marketing. R&D expenses increased 6% to $88.5 million.
• Debt Restructuring: In February 2025, the Company exchanged $659.3 million of its 2027 Convertible Notes for $600.0 million of new 2031 Convertible Notes. This resulted in a $13.7 million gain on extinguishment recorded in Other income (expense), net.
• Other Income: Other income improved significantly from a $29.1 million loss in Q1 2024 (driven by unrealized losses on Lunit equity) to a $7.9 million gain in Q1 2025, primarily due to the debt extinguishment gain, partially offset by a $5.0 million impairment of a non-marketable equity investment.
• Treasury Stock: The Company repurchased $45.0 million of its common stock in February 2025 as part of the debt exchange transaction.

Guidance, Outlook, and Risks

• Liquidity: Management believes current cash and anticipated cash flows are sufficient to meet requirements for more than 12 months. The Company maintains an At-The-Market (ATM) offering program with up to $400 million capacity, though no shares have been sold under it as of March 31, 2025.
• Product Outlook: The Company expects to expand the Shield platform into lung cancer screening and multi-cancer detection. The Shield test was selected for the NCI Vanguard study in January 2025.
• Legal Contingencies:
  • TwinStrand/UW: A jury awarded $83.4 million in damages for patent infringement in late 2023. The Company is contesting this via post-trial motions and potential appeal.
  • Natera: A jury awarded Guardant $292.5 million for false advertising in November 2024. Post-trial hearings are scheduled for mid-2025.
  • Tempus & CSHL: New patent infringement suits were filed by Tempus and Cold Spring Harbor Laboratory in March 2025. Guardant also filed a suit against Tempus in June 2024.
• Risks: Key risks include reimbursement variability from payers, the outcome of ongoing litigation, and the ability to achieve commercial adoption for new screening products.

Investor Verification Checklist

• Verify the status and potential impact of the $83.4 million TwinStrand liability and the $292.5 million Natera award pending post-trial resolutions.
• Monitor reimbursement rates for the Shield test and Guardant360 suite, as revenue recognition relies heavily on estimated variable consideration from payers.
• Assess the sustainability of Sales and Marketing expense growth (up 30% YoY) relative to revenue growth and the timeline for profitability.
• Review the terms of the new 2031 Convertible Notes (1.25% coupon, conversion price ~$62.22) and their impact on future dilution.
• Track the progress of the Shield Lung and Multi-Cancer Detection clinical studies and regulatory approvals.